ClinicalTrials.gg

Bipolar Disorder clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,686 studies for Bipolar Disorder across more than 10 countries. 268 are recruiting or about to start. 1,084 of them are mainly about Bipolar Disorder (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,072 studies for Bipolar Disorder. How that becomes 1,685 here

This page counts the studies the registry files under Bipolar Disorder, and those it files under no condition that list Bipolar Disorderthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,072Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −23List Bipolar Disorder as a condition, but the registry did not file them under itMost often written as “Bipolar Disorder With Psychotic Features” (8), “Severe Bipolar Disorder With Psychotic Features” (2), and “Bipolar Disorder With Psychosis” (2). The registry filed them under other conditions only, most often Schizophrenia (15) and Psychotic Disorders (14).
  3. −364Match it another way49 name it in the title, 2 in a keyword, and 313 by a synonym or other text the search reads.
  4. 1,685The count on this page14 of them list Bipolar Disorder in their own words; the registry filed them under no condition.

Status

Completed
1,057
Recruiting
208
Status unknown
146
Terminated
117
Withdrawn
48
Not yet recruiting
46

Phase

Phase 4
232
Phase 3
231
Phase 2
178
Phase 1
77
Early Phase 1
12

Where

United States
837
Canada
134
France
102
China
78
Spain
53
Denmark
49

Who develops what

Add Bipolar Disorder to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 9 companies, 7 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare AbbVie, Bristol-Myers Squibb and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
OlanzapineEarlier only
Evidence
  • NCT00490971 · Johnson & Johnson · Phase 3 · comparator · “Olanzapine” · registered Jun 2007
  • NCT00391222 · Johnson & Johnson · Phase 3 · comparator · “Olanzapine” · registered Oct 2006
  • NCT00329108 · Viatris Inc. · Phase 4 · comparator · “olanzapine” · registered May 2006
  • NCT00159796 · Organon & Co. · Phase 3 · comparator · “Olanzapine” · registered Sep 2005
  • NCT00159783 · Organon & Co. · Phase 3 · comparator · “Olanzapine” · registered Sep 2005
Eli Lilly and Company47% of its industry studiesUS: off-patent, 30 generics marketedEU: off-patent, 7 generics authorized00 studies
quetiapineEarlier only
Evidence
  • NCT00771134 · H. Lundbeck A/S · Phase 2 · comparator · “Quetiapine” · registered Oct 2008
  • NCT00622245 · H. Lundbeck A/S · Phase 2 · comparator · “Quetiapine fumarate” · registered Feb 2008
  • NCT00309699 · Johnson & Johnson · Phase 3 · comparator · “Quetiapine” · registered Mar 2006
AstraZeneca72% of its industry studiesUS: off-patent, 21 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
azetukalner☆ Track2 live phase-3 studies: NCT07217860, NCT07172516Xenon Pharmaceuticals Inc.

The 1 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 Jun 2027 est.xanomeline, trospium chloride · Bristol-Myers Squibb · Phase 3 named, not the main aimNCT07140913 A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine — primary endpoint: Change from baseline in Young Mania Rating Scale (YMRS) at Week 5 · 424 enrolled
  • Nov 2027 est.brenipatide · Eli Lilly and Company · Phase 2 main aimNCT07286175 A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) — primary endpoint: Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion · 400 enrolled
  • Nov 2027 est.icalcaprant · AbbVie · Phase 2 main aimNCT06696755 A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder — primary endpoint: Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total score · 195 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Bipolar Disorder studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antipsychotics 5 open · GLP-1 receptor agonists 3 open · SSRIs 2 open · Serotonin receptor agonists 2 open · NSAIDs 1 open

Coming up

96studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger. 38 (18%) take children under 18. 2 (1%) are for women only and 0 (0%) for men only; 51 (25%) take healthy volunteers.

Recruiting studies that take each age, of 208
AgeWomenMen
1016 (8%)16 (8%)
18182 (88%)180 (87%)
30184 (88%)182 (88%)
40179 (86%)178 (86%)
50169 (81%)169 (81%)
65146 (70%)146 (70%)
7575 (36%)75 (36%)
8566 (32%)66 (32%)

Across all 1,685 studies, recruiting or not: 68% stop at 75 or younger and 58% at 65; 18% take children; 2% are for women only and <1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Bipolar Disorder studies take

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 114 mo10–43 · 22 studies——
Phase 233 mo20–62 · 56 studies—49 mo21–63 · 42 studies
Phase 337 mo21–60 · 43 studies33 mo17–49 · 29 studies—
Phase 443 mo25–60 · 44 studies—50 mo25–61 · 39 studies
Interventional, no phase37 mo23–58 · 359 studies—39 mo23–58 · 357 studies
Observational64 mo31–118 · 105 studies—65 mo39–119 · 95 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,686. Browse all 1,686 → or search them.